Tyrosine kinase inhibitor treatment for renal cell carcinoma with inferior vena cava tumour thrombus: a quantitative summary.

Presurgical axitinib therapy increases fibrotic reactions within tumor thrombus in renal cell carcinoma with thrombus extending to the inferior vena cava. Keywords: neoadjuvant; thrombus; systemic treatment; tyrosine kinase inhibitor; cava thrombus EN neoadjuvant thrombus systemic treatment tyrosine kinase inhibitor cava thrombus 566 568 3 04/25/23 20230501 NES 230501 Abbreviations GRADE Grading of recommendations assessment, development and evaluation IO immunotherapies IVC inferior vena cava TKI tyrosine kinase inhibitor VTT venous tumour thrombus Renal cell carcinoma (RCC) with venous tumour thrombus (VTT) extension into the inferior vena cava (IVC) occurs in about 4%-15% of cases [[1]]. Neoadjuvant, thrombus, systemic treatment, tyrosine kinase inhibitor, cava thrombus. [Extracted from the article]